Pfizer COX-2 Marketing, Safety Practices Questioned By DoJ
This article was originally published in The Tan Sheet
Executive Summary
Pfizer is working to supply the Justice Department and several state attorneys general with materials related to the company's handling of marketing and safety issues associated with Celebrex and Bextra
You may also be interested in...
Merck Shores Up Vioxx Legal Reserve; SEC Initiates Formal Inquiry
Merck's $675 mil. legal reserve related to Vioxx appears to be only a starting point in ongoing litigation
Merck Shores Up Vioxx Legal Reserve; SEC Initiates Formal Inquiry
Merck's $675 mil. legal reserve related to Vioxx appears to be only a starting point in ongoing litigation
Merck Shores Up Vioxx Legal Reserve; SEC Initiates Formal Inquiry
Merck's $675 mil. legal reserve related to Vioxx appears to be only a starting point in ongoing litigation